The FDA approved the iDose TR for the lowering of IOP in patients with ocular hypertension or open-angle glaucoma, according to a press release from Glaukos.
The iDose TR (travoprost intracameral implant) 75 mcg is “designed to continuously deliver 24/7 therapeutic levels of a proprietary formulation of travoprost inside the eye for extended periods of time” to address issues with patient compliance and side effects caused by topical glaucoma treatments, according to the release.
The implant previously demonstrated positive results in the phase 3 GC-010 and GC-012 trials, which